A miR-199a/miR-214 Self-Regulatory Network via PSMD10, TP53 and DNMT1 in Testicular Germ Cell Tumor

Bi-Feng Chen1,2, Yick-Keung Suen1, Shen Gu1, Lu Li1 & Wai-Yee Chan1

1The Chinese University of Hong Kong - Shandong University Joint Laboratory on Reproductive Genetics, School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China, 2Department of Biological Science and Biotechnology, School of Chemical Engineering and Life Sciences, Wuhan University of Technology, Wuhan, Hubei, China.

It was previously demonstrated that microRNA-199a (miR-199a) was down-regulated in testicular germ cell tumor (TGCT) partially caused by hypermethylation of its promoter. miR-199a is encoded by two loci in the human genome, miR-199a-1 on chromosome (Chr) 19 and miR-199a-2 on Chr 1. Both loci encode the same miR-199a. Another microRNA, microRNA-214 (miR-214), also locates on Chr 1. Previous study revealed that it is co-transcribed with miR-199a-2. However, the biological significance of the co-expression of miR-199a and miR-214 remains largely unknown. In this study, we determined that miR-199a and miR-214 were concordantly expressed in NT2 cells and TGCT patient tissues. After 5-aza treatment, miR-199-3p/5p and miR-214 expression was significantly increased. Silencing of DNMT1 with siRNA restored the expression of miR-199a and miR-214, accompanied by de-methylation of the promoters of miR-199a-1/2. TP53 down-regulated the expression of DNMT1 in NT2 cells and overexpression of TP53 restored the expression of miR-199-3p/5p and miR-214. In addition, silencing of PSMD10 up-regulated the expression of TP53, while miR-214 over-expression resulted in PSMD10 down-regulation and TP53 up-regulation. Collectively, our findings highlighted a miR-199a/miR-214/PSMD10/TP53/DNMT1 self-regulatory network, which might be a potential therapeutic target in the treatment of TGCT.
DNMT1 regulates miR-199a expression via mediating DNA methylation of miR-199a-1 promoter region. Thus, it was suspected that DNMT1 also regulates miR-199a expression via mediating DNA methylation of miR-199a-2 promoter region in TGCT.

It was reported that the transcription of miR-199a-2 and miR-214 is regulated by the same promoter (miR-199a-2 promoter) as a single transcript in both human and mouse. Co-expression of miR-199a and miR-214 was observed during normal development and in various diseases. However, the significance of co-expression of miR-199a and miR-214 has not been fully elucidated. Besides, various studies showed that TP53 represses the transcription activity and expression of DNMT1. Interestingly, a more recent study reported that TP53 represses the transcription activity and expression of DNMT1 via directly targeting Gankyrin (also known as PSMD10), a negative regulator of tumor suppressor TP53.

Concordant expression of miR-199a and miR-214 in TGCT. Since it was demonstrated that the promoters of miR-199a at both loci (Chr 1 and Chr 19) were hypermethylated, and the co-transcription of miR-199a-2 and miR-214 was directed by the miR-199a-2 promoter, it is conceivable to propose that miR-214 showed similar expression pattern as miR-199a in TGCT. Indeed, qPCR results indicated that miR-214 was down-regulated in NT2 cells with more than 90-fold change when compared with HT cells (Fig. 1A). Moreover, the expression of miR-214 mRNA in clinical samples was also tested. miR-214 was significantly down-regulated in embryonal carcinoma compared to normal tissues (Fig. 1B). These results were consistent with the expression levels of miR-199a-3p and miR-199a-5p (two mature miRNAs of miR-199a) in embryonal carcinoma and NT2 cell lines. Moreover, treatment with 5-aza restored the expression of miR-214, miR-199a-3p and miR-199a-5p in NT2 cells (Fig. 1C). These data suggested that miR-199a and miR-214 were concordantly expressed in TGCT, confirming the co-expression of miR-199a and miR-214.

DNMT1 regulates the expression of miR-199a/miR-214 via promoter methylation in TGCT. Consistent with the upregulation of DNMT1 in embryonal carcinoma, DNMT1 was overexpressed in NT2 cells and embryonal carcinoma samples when compared with HT cells and normal testis tissues (Fig. 2A, B, C). Next, to select the siRNAs used to knock down DNMT1 in NT2 cells, the knock-down efficiencies of different siRNAs were compared. Results showed that si2354 had the best knock-down efficiency. Therefore, it was selected for subsequent experiments (Fig. 2D, E). When assessing the expression of miR-214 and miR-199a, it was found that knocking down DNMT1 increased the expression of mature miR-214, miR-199a-3p and miR-199a-5p, respectively, in NT2 cells (Fig. 2F). In addition, methylation-specific PCR (MSP) was used to examine the promoter methylation changes of miR-199a-1. Five sets of MSP primers were designed, of which two sets of primers focused on two CpG rich regions of miR-199a-1, and three sets of primers focused on three CpG rich regions of miR-199a-2. Each set of primers contained two pairs of primers to amplify either methylated or unmethylated alleles. miR-199a-1 is localized in Chr 19, with a size of 71bp (+1 to +71) in the human genome (10928102 to 10928172). The two regions selected for MSP analysis, based on their CpG content and being at the 5’ end of the gene, are (~472 to ~97) for M1/U1 and (~472 to ~11) for M2/U2. miR-199a-2 is localized in Chr 1, with a size of 110 bp (+1 to +110) in the human genome (172113675 to 172113784). The three regions selected for MSP analysis are (~21 to +396) for M1/U1, (~65 to +374) for M2/U2 and (~21 to +100) for M3/U3. These three regions were previously identified to be in the potential promoter of miR-199a-2. MSP results showed that the promoter methylation levels of miR-199a in the two loci were correspondingly decreased after transfection with siDNMT1 (si2354) in NT2 cells (Fig. 2G). In addition, knocking down DNMT1 led to the elevation of pri-miR-199a-1/2 and pri-miR-214 (Fig. 2H). However, there are other transcription factors such as TWIST1, REST and CREB that are potentially involved in the regulation of miR-199a/miR-214 and would possibly affect the operation of the miR-199a/miR-214/PSMD10/TP53/DNMT1 network.

TP53 represses the expression of DNMT1 and increases the expression of miR-199a/miR-214 in TGCT. The expression of TP53...
in HT cells and NT2 cells, as well as in clinical samples were compared by RT-qPCR. TP53 showed 2-fold down-regulation in NT2 cells (Fig. 3A). Results of Western blot analysis corroborated with this observation (Fig. 3B). In clinical samples, TP53 was significantly down-regulated in embryonal carcinoma compared to normal testis tissues (Fig. 3C). This is in agreement with the low expression of TP53 in the majority of TGCT samples. When we overexpressed TP53 in NT2 cells with wide-type TP53 expression vector (pEGFP-TP53), we found that TP53 could inhibit the expression of DNMT1 (Fig. 3D, E, F). In addition, a statistically significant inverse correlation was observed between TP53 mRNA level and DNMT1 mRNA level in clinical samples ($r = -0.609$, $p = 0.001$. Pearson’s correlation; Fig. 3G). To investigate whether TP53 regulates DNMT1 expression via modulating DNMT1 promoter activity, dual luciferase assay was employed to quantify the regulation of DNMT1 promoter activity gene by wild-type TP53 in NT2 cells. Fig. 3H showed the construct of pGL3-DNMT1 promoter luciferase reporter vector. Compared with pGL3-Basic vector, pGL3-DNMT1 promoter vector showed much higher luciferase activity. Co-transfection of pGL3-Basic vector with pEGFP-TP53 or pEGFP-N1 in NT2 cells, resulted in no significant difference between the two groups. However, co-transfection of pGL3- DNMT1 promoter vector with pEGFP-TP53 or pEGFP-N1 in NT2 cells showed that wild-type TP53 decreased DNMT1 promoter activity to 40% of the pEGFP-N1 control vector (Fig. 3I). Notably, overexpression of TP53 restored the expression of mature miR-214, miR-199a-3p and miR-199a-5p, respectively, in TGCT (Fig. 3J). On the other hand, TP53 is known to involve in posttranscriptional regulation of microRNA biogenesis. To prove the elevation of mature miR-199a-3p/5p and miR-214 due to the regulation of TP53 on the transcription of pri-miR-199a-1/2 and pri-miR-214, the expression of pri-miR-199a-1/2 and pri-miR-214 were assessed after overexpression of TP53 in NT2 cells, and found that TP53 increased the primary transcription of miR-199a and miR-214 (Fig. 3K). In addition, to rule out the involvement of TWIST1, REST and CREB, the expression of TWIST1, REST and CREB were examined after overexpression of TP53 in NT2 cells. No significant change in the expression level of these transcription factors was observed (Fig. 3K). These findings
revealed that TP53 repressed DNMT1 promoter activity and expression level, and enhanced the expression of miR-199a/miR-214. This effect of TP53 did not involve TWIST1, REST or CREB.

**PSMD10 negatively regulates the expression of TP53 in TGCT.** It was previously reported that PSMD10 is a negative regulator of tumor suppressor TP53. To confirm the negative regulator role of PSMD10 on TP53, the expression of PSMD10 in HT cells and NT2 cells, as well as in clinical samples were examined. The expression level of PSMD10 showed 3-fold up-regulation in NT2 cells (Fig. 4A, B). The level of PSMD10 was also significantly higher in embryonal carcinoma (Fig. 4C). When si373 was used to knock down PSMD10 in NT2 cells, the expression of TP53 in NT2 cells increased (Fig. 4D, E, F, G). Moreover, correlation study showed that PSMD10 mRNA level was inversely correlated with TP53 mRNA level in clinical samples ($r = -0.409, p = 0.042$. Pearson’s correlation; Fig. 4H).

**miR214 positively regulates the expression of TP53 via directly targeting PSMD10 in TGCT.** It is known that PSMD10 was a direct target of miR-214 in myeloma. To validate the direct targeting of miR-214 on PSMD10 in TGCT, a dual luciferase assay was performed. We constructed the pmirGLO-PSMD10 3’UTR reporter vector containing the putative miR-214 binding sites (Fig. 5A). The pmirGLO-PSMD10 3’-UTR reporter vector was co-transfected with internal control pRL-TK renilla luciferase vector into NT2 cells. Reporter luciferase activity was measured. Ratio of relative activity was calculated within group independent of each other. (J) Mature miR-214, miR-199a-3p and miR-199a-5p mRNAs expression after transfection of pEGFP-TP53 vector into NT2 cells. (K) The mRNAs expression of pri-miR-214, pri-miR-199a-1/2, TWIST1, REST and CREB after overexpression of TP53 in NT2 cells.
performed using Pearson's correlation analysis. Compared with normal testicular tissue\(^1\), \(^1\) more detailed analyses demonstrated that the promoters of miR-199a at both loci (Chr 1 and Chr 19) were almost completely methylated in TGCT when hypermethylation in TGCT. Previous studies showed that miR-214 acted as a tumor suppressor via downregulation of certain oncogenes [PSMD10\(^2\), \(\beta\)-catenin\(^3\), FGFR1\(^4\), and Ezh2\(^5\)] in these different solid cancers. In our study, we demonstrated that in embryonal carcinoma and NT2 cells, miR-214 was also down-regulated. Inhibition of PSMD10 induced an increase of TP53 mRNA and protein levels. In addition, miR-214 was shown to directly targeted and down-regulated the expression of PSMD10, which subsequently up-regulated the expression of TP53. Moreover, a statistically significant inverse correlation between miR-214 mRNA level and PSMD10 mRNA level, while a statistically significant positive correlation between miR-214 mRNA level and TP53 mRNA level was observed in clinical samples. These data confirmed a tumor suppressor role for miR-214 in TGCT.

### Discussion

Cancer was initially regarded as a disease of cell proliferation caused by mutations in genes that control proliferation and the cell cycle.\(^6\) This is the Somatic Mutation Theory.\(^6\) However, since the inception of epigenetics in the 1940s, discoveries implicating its role in cancer have been mounting continuously. More importantly, global changes in epigenetic regulation have been regarded as a hallmark of cancer. It is now realized that initiation and progression of cancer involves epigenetic abnormalities along with genetic alterations.\(^7\) During the past decade, the epigenetics factors have changed from just one recognized marker, DNA methylation, to a variety of others, including a wide spectrum of histone modifications and microRNAs.\(^8\) As the first identified epigenetic modification, DNA methylation has been widely studied. Dysregulation of DNA methylation has been found in cancer as a typical hallmark, and its consequence is the silencing of genes and noncoding RNAs.\(^9\)

miR-199a is a typical example of silenced miRNA partially caused by promoter DNA hypermethylation in TGCT. Previous studies demonstrated that the promoters of miR-199a at both loci (Chr 1 and Chr 19) were almost completely methylated in TGCT when compared with normal testicular tissue.\(^1\), \(^1\) More detailed analyses showed that miR-199a-5p, one of its two derivatives, suppressed TGCT invasion and proliferation via directly targeting PODXL and MAFB.\(^1\), \(^1\) On the other hand, miR-199a-3p, its other derivative, was shown to negatively regulated DNA methylation in TGCT, partly through targeting DNMT3A. Overexpression of miR-199a-3p restored the expression of APC and MGMT tumor-suppressor genes in NT2 cells by affecting DNA methylation of their promoter regions.\(^1\) Collectively, these data assigned a tumor suppressor role to miR-199a in TGCT. On the other hand, low expression of miR-214 has been observed in different types of cancer, such as myeloma, hepatocellular carcinoma, colorectal cancer, breast cancer, and primary central nervous system lymphomas (PCNSL).\(^1\) Moreover, it has been demonstrated that miR-214 acted as a tumor suppressor via downregulation of certain oncogenes [PSMD10, \(\beta\)-catenin, FGFR1, and Ezh2] in these different solid cancers. In our study, we demonstrated that in embryonal carcinoma and NT2 cells, miR-214 was also down-regulated. Inhibition of PSMD10 induced an increase of TP53 mRNA and protein levels. In addition, miR-214 was shown to directly targeted and down-regulated the expression of PSMD10, which subsequently up-regulated the expression of TP53. Moreover, a statistically significant inverse correlation between miR-214 mRNA level and PSMD10 mRNA level, while a statistically significant positive correlation between miR-214 mRNA level and TP53 mRNA level was observed in clinical samples. These data confirmed a tumor suppressor role for miR-214 in TGCT.

As a master regulator, miRNA is involved in multiple cellular processes during normal development and diseases.\(^1\) Previous studies mainly focused on the elucidation of miRNA functions. However, the question of how microRNA expression is regulated was rarely asked. In the present study, we explored the mechanism of the down-expression of miR-199a/miR-214 in TGCT. Early studies indicated that miR-199a-2 and miR-214 were co-transcribed with the promoter of miR-199a-2, and co-expression of miR-199a and miR-214 has been observed in various systems.\(^1\), \(^1\) Notably, concordant expression of miR-199a and miR-214 was also observed in TGCT. Since it was reported that silencing of miR-199a-1/2 was partially caused by promoter DNA hypermethylation, the expression of miR-214, miR-199a-3p, and miR-199a-5p, respectively, were correspondingly up-regulated after treatment with 5-aza. Moreover, we showed that DNMT1, the maintenance DNA methyltransferase, inhibited the expression of primary and mature miR-199a/miR-214 via affecting the promoter DNA methylation of miR-199a-1 and miR-199a-2/miR-214 in TGCT. In unraveling the regulatory mechanisms of miR-199a/miR-214 expression in greater detail, we further found that TP53 repressed the transcription activity and expression of DNMT1 as previously reported, which suggested that TP53 is a potential positive regulator of miR-199a/miR-214. Indeed, over-expressed TP53 would up-regulate the expression of primary
and mature miR-199a/miR-214, respectively, in TGCT. Therefore, a new miR-199a/miR-214/PSMD10/TP53/DNMT1 self-regulatory network was suggested in TGCT progression, in which TP53 was activated by miR-214 and participated in the positive regulation of miR-199a/miR-214 via repressing DNMT1 (Fig. 6). However, previous study reported that DNMT1 was not expressed in seminoma, but upregulated in embryonal carcinoma. Thus the regulatory network suggested in the current study might only operate in non-seminoma and not in seminoma. Several well-known regulators of miR-199a and miR-214 expression in systems other than TGCT, such as TWIST1, REST and CREB, were not affected after DNMT1 siRNA treatment and overexpression of TP53 in NT2 cells. These results suggested that the regulation of miR-199a and miR-214 is highly complex and the regulatory network is tissue and/or tumor dependent. The miR-199a/miR-214/PSMD10/DNMT1 self-regulatory network identified in the current study could regulate the expression of miR-199a/miR-214 in TGCT. However, the existence of other regulatory pathway cannot be ruled out.

The miR-199a/miR-214/PSMD10/DNMT1 regulatory network contributed to the down-regulation of miR-199a, miR-214, and TP53, respectively, as well as the up-regulation of DNMT1 in TGCT, and partly explains the mechanism involved in DNA hypermethylation of miR-199a promoter in TGCT. However, DNMT3B and DNMT3L, the other DNA methyltransferases, were not examined in this study. DNMT3L specifically expressed in TGCTs and EC cell lines and was essential for the growth of human EC. The small interfering RNAs (siRNAs) specifically targeting DNMT1 (siDNMT1), namely, si1617, si2354 and si3437, respectively, and DNMT3L, and partly explain the mechanism involved in DNA hypermethylation of miR-199a promoter regions. Since DNMT3A did not affect DNA methylation of the miR-199a promoter regions and knocking down DNMT1 did not cause complete demethylation of the miR-199a-1/2 promoter regions, it is reasonable to assume that DNMT3B, DNMT3L, or both might also act as a regulator of miR-199a/miR-214 expression. Elucidation of the role of DNMT3B and DNMT3L in miR-199a/miR-214 silencing will help us understand better the mechanism of DNA methylation and involvement of DNMTs in the regulation of miR-199a/miR-214 in TGCT.

In summary, our findings highlight a miR-199a/miR-214/PSMD10/DNMT1 self-regulatory network, the dysfunction of which may contribute to tumor survival and progression of TGCT. Our study offers new insight into the biological significance conferred by the co-expression of miR-199a and miR-214, and provide a potential therapeutic approach in targeting miR-199a/miR-214/PSMD10/DNMT1 regulatory network for the treatment of TGCT.

Methods

Primary TGCT specimens. Genomic RNA of 9 embryonal carcinoma (EC) obtained from TGCT patients were purchased from Oncomatrix (San Marcos, CA, USA). Normal testicular RNA (16 cases) were purchased from Zyagen (San Diego, CA, USA). Each RNA samples was isolated from a single individual.

Cell culture and transfection. Ntera 2 (NT2) and Hs 1.Tes (HT) cell lines were purchased from ATCC (Manassas, VA, USA) supplemented with 10% FBS and incubated in a 37°C humidified incubator supplied with 5% CO2. Synthetic double-stranded miR-214 mimics, scramble oligonucleotides used as negative control (NC) (GenePharma, Shanghai, China) at a final concentration of 20 nM were introduced into NT2 cells by Lipofectamine 2000 kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. Cells were harvested at 48 hours after transfection. For demethylation analysis, 1 × 10^4 NT2 cells were seeded for 24 h and treated with 2.5 μM or 5 μM of 5-aza-2-deoxycytidine (5-aza) (Sigma, St Louis, MO, USA) for 72 h.

Inhibition of DNMT1, PSMD10 expression and overexpression of TP53. The small interfering RNAs (siRNAs) specifically targeting DNMT1 (siDNMT1), namely, si1617, si2354 and si3437, respectively, and PSMD10 (siPSMD10), namely, si373,
The expression of miR-214, TP53, PSMD10 and DNMT1 in embryonal carcinoma and normal testis tissues were compared by the unpaired 2-tailed t-test. The relationship between miR-214 and PSMD10 mRNA expression levels, miR-214 and TP53 mRNA expression levels, TP53 and PSMD10 mRNA expression levels, TP53 and DNMT1 mRNA expression levels were analyzed by Pearson’s correlation. The differences between samples analyzed by luciferase assay and RT-qPCR were determined by two-tailed Student’s t-test. The expression of miR-199a-2, miR-199a-3p, miR-199a-5p and miR-214 were measured using the well-established semiloop RT-qPCR method as previously described, and the level of miRNAs expression were normalized by U6 RNA. Real-time PCR was performed with a standard SYBR-
1. Chen, C. Z. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 353, 1768–1771 (2005).
2. Baylin, S. B. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2 Suppl 1, S4–11 (2005).
3. Li, W. & Chen, B. F. A aberrant DNA methylation in human cancers. J Huazhong Univ Sci Technolog Med Sci 33, 798–804 (2013).
4. Lehner, M., Boshoff, C. & Beck, S. Cancer epigenome. Adv Genet 70, 247–276 (2010).
5. Chen, B. F. & Chan, W. Y. The de novo DNA methyltransferase DNMT3A in development and cancer. Epigenetics 9, 669–677 (2014).
6. Gilbert, D., Rapley, E. & Shipley, J. Testicular germ cell tumours: predisposition genes and the male germ cell niche. Nat Rev Cancer 11, 278–288 (2012).
7. Boul, G. J. & Motzer, R. J. Testicular germ-cell cancer. N Engl J Med 337, 242–253 (1997).
8. Oosterhuis, J. W. & Looijenga, L. H. Testicular germ-cell tumours in a broader perspective. Nat Rev Cancer 5, 210–222 (2005).
9. Burger, H., Nooter, K., Boersma, A. W. M., Kortland, C. J. & Stoter, G. Expression of the testis-specific gene SIM1 in testicular germ cell tumours. Br J Cancer 77, 1562–1567 (1998).
10. Koch, S., Mayer, F., Honecker, F., Schittenhelm, M. & Bokemeyer, C. Efficacy of P53 represses E-cadherin overexpression in lung cancer. Cancer Res 65, 5588–5595 (2005).
11. Gu, S. et al. Molecular mechanisms of regulation and action of microRNA-199a in testicular germ cell tumor and glioblastomas. Proc Natl Acad Sci U S A 108, 11122–11127 (2011).
12. Lee, Y. B. et al. Twist-1 regulates the miR-199a/214 cluster during development. Nucleic Acids Res 37, 123–128 (2009).
13. Sakurai, K. et al. MicroRNAs miR-199a-3p and -3p target the Brm subunit of SWI/SNF to generate a double-negative feedback loop in a variety of human cancers. Cancer Res 71, 1680–1689 (2011).
14. Wienholds, E. et al. MicroRNA expression in zebrafish embryonic development. Science 309, 310–311 (2005).
15. Yi, R. & et al. Morphogenesis in skin is governed by discrete sets of differentially expressed microRNAs. Nat Genet 38, 356–362 (2006).
16. van Rooij, E. et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 103, 18255–18260 (2006).
17. Fischer, L. et al. Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas. Neuro Oncol 13, 1090–1098 (2011).
18. Santha-Kumar, D. et al. Combined agonist-antagonist genome-wide functional screening identifies broadly active antiviral microRNAs. Proc Natl Acad Sci U S A 107, 13830–13835 (2010).
19. Lin, R. K. et al. Dysregulation of p53/Skp1 control leads to DNA methyltransferase-1 overexpression in lung cancer. Cancer Res 70, 5807–5817 (2010).
20. Kwok. HPV-16 E6 upregulation of DNMT1 through repression of tumor suppressor p53. Oncol Rep 24, 1599–1604 (2010).
21. Cheng, J., Suresp, N. & Leung, P. C. Inhibition of p53 represses E-cadherin expression by increasing DNA methyltransferase-1 and promoter methylation in serous borderline ovarian tumor cells. Oncogene 30, 3930–3942 (2011).
22. Cheng, J. C., Auer, S. N. & Leung, P. C. Inhibition of DNA repair in serous borderline ovarian tumor cells by accentuating PI3K/Akt-mediated suppression of E-cadherin. Oncogene 30, 1020–1031 (2011).
23. Misiewicz-Krzeminska, I. et al. Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA methylation. Haematologica 98, 640–648 (2013).
24. Qiu, W. et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33, e179 (2005).
25. Herman, J. G. & Graff, J. R. Hypermethylation of the Polycomb Ezh2 methyltransferase. Cancer Res 62, 1607–1614 (2002).
26. Sun, W., Li, W. Y., Huang, H. D., Shy, J. Y. & Chien, S. microRNA: a master regulator of cellular processes for bioengineering systems. Annu Rev Bioeng 12, 1–27 (2010).
27. Bushati, N. & Cohen, S. M. microRNA functions. Annu Rev Cell Dev Biol 23, 175–205 (2007).
28. Netto, G. J. et al. Global DNA hypomethylation in intratubular germ cell neoplasia and seminoma, but not in nonseminomatous male germ cell tumors. Mod Pathol 21, 1337–1344 (2008).
29. Minami, K. et al. DNMT3L is a Novel Marker and Is Essential for the Growth of Human Embryonal Carcinoma. Clin Cancer Res 16, 2751–2759 (2010).
30. Araki, E., Nakagawa, T., Waki, Ushijima, S., Fujimoto, H. & Kanai, Y. DNA methyltransferase 3B expression is associated with poor outcome of stage I testicular seminoma. Histopathology 60, E12–E18 (2012).
31. Chen, C. et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33, e179 (2005).
32. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D. & Baylin, S. B. Methylated-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93, 9821–9826 (1996).

Acknowledgments

This work was supported by funds provided by the Chinese University of Hong Kong, Vigonica Ltd, International, and the CUKH-Shandong University Joint Laboratory.

Author contributions

B.F.C. planned the research, performed the experiments and drafted the manuscript. Y.K.S., S.G. and L.L. offered help in the entire project and carefully read the manuscript. W.Y.C. and S.G. contributed to the whole project and provided the manuscript. All authors have read and approved the final version of the manuscript.

Additional information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Chen, B.-F., Suen, Y.-K., Gu, S., Li, L. & Chan, W.-Y. A miR-199a/miR-214 Self-Regulatory Network via PSMD10, TP53 and DNMT1 in Testicular Germ Cell Tumor. Sci. Rep. 4, 6413; DOI:10.1038/srep06413 (2014).

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.